IPO Boutique Research, Color & More Information for Subscribers
A storyline that developed in December 2014 and has carried over into 2015 thus far is the massive valuations given in rounds of private funding to company’s who eventually intend on going public. We wrote about that issue in January but that same issue is rearing its head again. On Tuesday, the Wall Street Journal[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Actavis Symbol: ACT Price: Last trade $284.00 Trade Date: 2/27 Shares: 14.79 million Underwriter(s) J.P. Morgan, Mizuho Securities, Wells Fargo Securities,[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Neurocrine Biosciences Symbol: NBIX Price: Last trade $37.33 Trade Date: 2/19 Shares: 6 million Underwriter(s) J.P. Morgan, Deutsche Bank Securities Rating=Subscription[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Phillips 66 Partners LP Symbol: PSXP Price: Last trade $78.83 Trade Date: 2/18 Shares: 5.25 million Underwriter(s) Barclays, J.P. Morgan, BofA[…]
This past week five IPOs debuted, one updated terms and seven new deals filed. It was another difficult week for the IPO market as two of the seven new deals planning to come to market were postponed and many others who held-over from prior weeks’ failed to come to market. Among the five who made[…]
Inovalon Holdings, by our account, was more than 20x oversubscribed. The deal was underwritten by some of the best in the business and the demand for the IPO turned into a $6.16 premium above the offering price–or a 23% gain upon opening. But almost immediately, the story changed and ‘INOV’ was suddenly not a desired[…]
Thursday Pricings (Priced Friday AM) Bellerophon Therapeutics (Nasdaq: BLPH) – According to the underwriter, the deal was priced below range and up-sized. ‘BLPH’ prices 5 million shares at $12 and will debut today. Great AJax Corp (NYSE: AJX) – According to the underwriters, the deal was downsized and priced below the $15-$17 range. ‘AJX’ priced[…]
The IPO scene has been relatively weak over the past two weeks. Many deals that have scheduled to come to market have been either postponed or subjected to ‘Day-to-Day’ status while, in theory, management mulls over valuation. However, the weakness will likely be subsided as a pair of deals debut today: Inovalon Holdings (Nasdaq: INOV)[…]
Thursday Expected Pricings Inovalon Holdings (Nasdaq: INOV) – Inovalon Holdings prices IPO $1.00 above the already upwardly-revised range. ‘INOV’ prices 22.2 million shares at $27.00 and will debut on Thursday (2/12). Invitae Corporation (NYSE: NVTA) – Invitae Corp. upsized and priced its IPO above the range. ‘NVTA priced 6.35 million shares at $16.00 and will[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. To subscribe to his secondary ratings, click here. Company: Transition Therapeutics Inc. Symbol: TTHI Price: Last trade $7.08 Trade Date: 2/12 Shares:[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. To subscribe to his secondary ratings, click here. Company: CAS Medical Symbol: CASM Price: Last trade $1.29 Trade Date: 2/11 Shares: 6.2[…]
Wednesday Autogenomics (Nasdaq: AGMX) – We have been informed by the underwriter that the deal will likely not price tonight. We will have more information when it becomes available. Sol-Wind Renewable Power (NYSE: SLWD) – The underwriter says that this deal will now price on Wednesday (2/11) in hopes of a Thursday (2/12) debut. Rest[…]
Coupons.Com went public on March 7 to very strong public demand. $COUP priced 10.5 million shares at $16.00 and opened 70% higher with a first trade of $27.15. The stock’s intra-day, $33.00, high happened on day one.By early August, the deal was trading below its offering price and on Monday the company reported dismal earnings[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. To subscribe to his secondary ratings, click here. Company: Idera Pharmaceuticals
This past week three IPOs debuted, five updated terms and three new deals filed. It was a tough week for many deals planning to come to market as just three of the eleven IPOs on the schedule priced and debuted.
Tuesday Avenue Financial Holding (Nasdaq: AVNU) Wednesday Autogenomic (Nasdaq: AGMX) Sol-Wind Renewable Power (NYSE: SLWD) Thursday Inovalon Holdings (Nasdaq: INOV) Invitae Corporation (NYSE: NVTA) Friday Bellerpheron Therapeutics (Nasdaq: BLPH) Great AJax Corp (NYSE: AJX) Day-to-Day Infraredx (Nasdaq: REDX) Inotek Pharmaceuticals Corporation (Nasdaq: ITEK) Eyegate Pharmaceuticals (Nasdaq: EYEG)
The week started with 11 deals “scheduled” to come to market with only three pricing and coming to market. We won’t focus on the eight deals that failed to price…but we will look at one of the deals that is making its debut today, Columbia Pipeline Partners (NYSE: CPPL). Columbia Pipeline Partners, the midstream affiliate[…]
Friday AltheaDx, Inc (Nasdaq: IDGX) – TBD Check-Cap Ltd (Nasdaq: CHEK) – TBD Columbia Pipeline Partners LP (NYSE: CPPL) – Columbia Pipeline Partners priced $2.00 above the range and upsized its offering. ‘CPPL’ priced 46.81 million shares at $23.00 and will debut on Friday. Easterly Government Properties (NYSE: DEA) – The deal has been priced[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. To subscribe to his secondary ratings, click here. Company: Ohr Pharmaceutical, Inc.
Thursday Debut Advanced Accelerator Applications S.A. (Nasdaq: AAAP) – The deal has been postponed due to management’s decision not to proceed with valuation AltheaDx, Inc (Nasdaq: IDGX)– The underwriter states that this deal will now price Thursday night (2/5) in anticipation of a Friday (2/6) debut. Asante Solutions, Inc. (Nasdaq: PUMP) – The underwriter states[…]